. "Oxybutyninum"@en . . . . . "* 193 L"@en . . . . . . . . . . . "Avoid alcohol."@en . . . . . "4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate"@en . . "Humans and other mammals"@en . "investigational"@en . "4-Diethylamino-2-butinyl alpha-cyclohexylmandelat"@en . "Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased."@en . "Oxybutynin"@en . . . . "# Tupker RA, Harmsze AM, Deneer VH: Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol. 2006 Aug;142(8):1065-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16924061 # Mijnhout GS, Kloosterman H, Simsek S, Strack van Schijndel RJ, Netelenbos JC: Oxybutynin: dry days for patients with hyperhidrosis. Neth J Med. 2006 Oct;64(9):326-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17057269 # Schollhammer M, Misery L: Treatment of hyperhidrosis with oxybutynin. Arch Dermatol. 2007 Apr;143(4):544-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17438194"@en . . "approved"@en . . . . . . . . . . . . . . . . . . . "5633-20-5"@en . . . . . . . . "4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester"@en . . . . . . . . . . "Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester"@en . . . . . . "Oxybutynin"@en . "For the treatment of overactive bladder."@en . . . . . . . "LD₅₀=1220 mg/kg (Orally in rats, Goldenthal)"@en . . . . . "91%-93%"@en . . "Rapidly absorbed from gastrointestinal tract."@en . "Oxibutinina"@en . . . . . "12.4-13.2 hours"@en . . . . . . . . . . . "Masakatsu Shibasaki, \"Method of producing oxybutynin and its derivatives.\" U.S. Patent US20040006243, issued January 08, 2004."@en . . "Oxybutynine"@en . " "@en . . . . . . . . . . "Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor."@en . . . . . . "Oxybutynin is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Oxybutynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine. Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin."@en . . . . . . "Take with food."@en . . "Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester"@en . . . . . . . . . . " "@en . .